Nanoparticle‐Based Photothermal Therapy for Breast Cancer Noninvasive Treatment

Advanced Materials, Journal Year: 2023, Volume and Issue: unknown

Published: Aug. 10, 2023

Rapid advancements in materials science and nanotechnology, intertwined with oncology, have positioned photothermal therapy (PTT) as a promising noninvasive treatment strategy for cancer. The breast's superficial anatomical location aesthetic significance render breast cancer particularly pertinent candidate the clinical application of PTT following melanoma. This review comprehensively explores research conducted on various types nanoparticles employed elaborates their specific roles mechanisms action. integration existing therapies is scrutinized, underscoring its potential synergistic outcomes. Additionally, underlying consequential modifications to tumor microenvironment after are elaborated from medical perspective. Future directions suggested, an emphasis development integrative platforms that combine multiple therapeutic approaches optimization nanoparticle synthesis enhanced efficacy. goal push boundaries toward comprehensive, clinically applicable

Language: Английский

---

Bioorthogonal-Activated In Situ Vaccine Mediated by a COF-Based Catalytic Platform for Potent Cancer Immunotherapy

Journal of the American Chemical Society, Journal Year: 2023, Volume and Issue: 145(9), P. 5330 - 5341

Published: Feb. 23, 2023

Personalized tumor vaccines have become a promising modality for cancer immunotherapy. However, in situ personalized generated from immunogenic cell death (ICD) and adjuvants are mired by toxic side effects unsatisfactory efficiency. Herein, functionalizing the reticular structure to optimize catalytic activity of materials, series biocompatible covalent organic framework (COF)-based catalysts been designed screened establishing bioorthogonal-activated vaccine an efficient safe way. Especially, pro-doxorubicin (pro-DOX) could be bioorthogonally activated COF-based Fe(II) catalysts, which elicited ICD released tumor-associated antigens (TAAs). This prodrug activation strategy minimize drug maximize treatment effects. More importantly, system also catalytically activate pro-imiquimod (pro-IMQ, TLR7/8 immune agonist), served as adjuvant amplify antitumor immunity. Notably, this not only facilitated strong response but prevented dose-dependent chemotherapeutic drugs, including systemic inflammation caused random distribution adjuvants. To best our knowledge, it is first time devise platform generating vaccine, would provide paradigm achieving secure robust

Language: Английский

---

J‐Aggregation Strategy toward Potentiated NIR‐II Fluorescence Bioimaging of Molecular Fluorophores

Advanced Materials, Journal Year: 2023, Volume and Issue: 36(1)

Published: Aug. 1, 2023

Molecular fluorophores emitting in the second near-infrared (NIR-II, 1000-1700 nm) window with strong optical harvesting and high quantum yields hold great potential for vivo deep-tissue bioimaging high-resolution biosensing. Recently, J-aggregates are harnessed to engineer long-wavelength NIR-II emitters show unique superiority tumor detection, vessel mapping, surgical navigation, phototheranostics due their bathochromic-shifted bands required slip-stacked arrangement aggregation state. However, despite preliminary progress of theoretical study structure-property relationships, further paradigms remain scarce lack on aggregated fashion. In this effort, how utilize specific molecular structure form packing motifs J-type exciton coupling is emphatically elucidated. First, several regulating strategies achieve containing intermolecular interactions external conditions positively summarized deeply analyzed. Then, recent reports theranostics systematically provide a clear reference direction promoting development organic fluorophores. Eventually, prospective efforts ameliorating clinical practices outlined.

Language: Английский

---

Tracking tumor heterogeneity and progression with near‐infrared II fluorophores

Exploration, Journal Year: 2023, Volume and Issue: 3(2)

Published: March 16, 2023

Abstract Heterogeneous cells are the main feature of tumors with unique genetic and phenotypic characteristics, which can stimulate differentially progression, metastasis, drug resistance. Importantly, heterogeneity is pervasive in human malignant tumors, identification degree tumor individual progression a critical task for treatment. However, current medical tests cannot meet these needs; particular, need noninvasive visualization single‐cell heterogeneity. Near‐infrared II (NIR‐II, 1000–1700 nm) imaging exhibits an exciting prospect non‐invasive monitoring due to high temporal‐spatial resolution. More importantly, NIR‐II displays more extended tissue penetration depths reduced backgrounds because significantly lower photon scattering autofluorescence than traditional near‐infrared I (NIR‐I) imaging. In this review, we summarize systematically advances made imaging, especially detection as well As visual inspection modality, shows promising prospects understanding differences envisioned have potential be used clinically.

Language: Английский

---

Augmenting Immunogenic Cell Death and Alleviating Myeloid‐Derived Suppressor Cells by Sono‐Activatable Semiconducting Polymer Nanopartners for Immunotherapy

Advanced Materials, Journal Year: 2023, Volume and Issue: 35(33)

Published: May 11, 2023

Inducing immunogenic cell death (ICD) by sonodynamic therapy (SDT) is promising for cancer immunotherapy, which however inefficient due to oxygen depletion that compromises SDT effect and mediates recruitment of immunosuppressive myeloid-derived suppressor cells (MDSCs). The fabrication sono-activatable semiconducting polymer nanopartners (SPNTi ) simultaneously augment ICD alleviate MDSCs immunotherapy reported. A polymer, hydrophobic hypoxia-responsive tirapazamine (TPZ)-conjugate, MDSC-targeting drug (ibrutinib) are encapsulated inside such SPNTi with surface shell a singlet (1 O2 )-cleavable amphiphilic polymer. TPZ ibrutinib serve as partners enlarge immunotherapeutic effect. Upon sono-activation, generate 1 break -cleavable polymers in situ liberations TPZ-conjugate tumor sites, consumed create severe hypoxic microenvironment, which, activated augmenting action, while alleviates promoting antitumor immunological In bilateral mouse model, -mediated results growth restraints primary distant tumors noteworthy precaution metastases. This study thus provides strategy high precision safety via overcoming post-treatment hypoxia targeting MDSCs.

Language: Английский

---